Furthermore, MM-151 showed efficacy against CRC tumors derived from patients who develop secondary resistance to EGFR blockade by cetuximab or panitumumab due to mutations in the ECD of EGFR (Arena et al., 2016). This evidence concerns the gene EGFR and colorectal carcinoma.